Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations

PURPOSE Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-11-04
DOI
https://doi.org/10.1200/jco-26-00280
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations

Nadège Corradini, Martin G. McCabe, Perrine Marec‐Bérard, Stéphanie Reynaud et al.
Journal of Clinical Oncology
Sarcoma Diagnosis and Treatment
article

Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations

Nadège Corradini, Martin G. McCabe, Perrine Marec‐Bérard, Stéphanie Reynaud, Victor Renault, Markus Metzler, Manuela Krumbholz, Ellen Blanc, Olivier Delattre, Sylvain Dureau, Nina Jehanno, Susan Ann Burchill, Éléonore Frouin, Camille Benoist, Birgit Geoerger, Sandra J. Strauss, Nathalie Gaspar, Eve Lapouble, Bernadette M. D. Brennan, Eleni M. Tomazou, Gudrun Schleiermacher, Piers Gaunt, Valérie Laurence, Lieke Mous, Gaëlle Pierron, Laura Kirton, Elizabeth Ann Roundhill, Jennifer A. Anderton, Samuel D. Abbou, Aurélie Guinot, Sarah Winter, Didier Surdez, Peter Peneder, Stelly Ballet, Marie‐Emmanuelle Legrier, Anne-Sophie Plissonnier, Anja L. Frei, Abigail Evans
article en

Abstract

PURPOSE Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.

Journal of Clinical Oncology
National Health Service (GB), Translational Research Institute (AU), University College London Hospitals NHS Foundation Trust (GB), Inserm (FR), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), University of Zurich (CH), Université Paris Sciences et Lettres (FR), Université Paris-Saclay (FR), St James's University Hospital (GB), Institut Gustave Roussy (FR), Universitätsklinikum Erlangen (DE), Centre Léon Bérard (FR), Translational Research in Oncology (FR), The Christie NHS Foundation Trust (GB), Cancer Research UK Clinical Trials Unit (GB), Comprehensive Cancer Center Erlangen (DE), Royal Manchester Children's Hospital (GB), St. Anna Children's Cancer Research Institute (AT), University College London (GB), Medical University of Vienna (AT), Institut Curie (FR)
Openalex Percentile: Top 13%
Sarcoma Diagnosis and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon